ALKEM5,111.00

Alkem Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersMANKINDTORNTPHARMIPCALABLUPINFORTISAUROPHARMALAURUSLABSBIOCONMcap ₹61,102 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations12,667.612,964.514,712.315,081.3
Other Income310.8493.7583.4599.6
Total Income12,978.413,458.315,295.615,680.9
Expenses
+ Cost of Materials Consumed3,294.63,440.43,565.43,648.3
+ Purchases of Stock-in-Trade1,628.91,514.01,694.51,663.3
+ Changes in Inventories14.1-190.1-167.1-188.7
+ Employee Benefit Expense2,201.02,453.92,837.12,952.8
+ Finance Costs112.4121.7160.8177.6
+ Depreciation & Amortisation299.3357.2382.1394.6
+ Other Expenses3,283.53,234.23,777.23,973.4
Total Expenses10,833.810,931.212,249.912,621.3
EBITDA2,245.52,512.23,005.23,032.2
EBIT1,946.22,155.02,623.22,637.6
Profit
PBT before Exceptional Items2,144.62,527.03,045.73,059.6
+ Exceptional Items-121.50.0-174.8-187.8
Pretax Income2,023.12,527.02,870.92,871.9
+ Current Tax422.3523.6619.7710.6
+ Deferred Tax-210.6-212.6-101.9-45.0
Tax Expense211.7311.0517.8665.6
+ Share of Associates & JVs0.0-0.6-2.0-2.1
Net Income1,811.52,215.42,351.22,204.2
+ Net Income — Continuing Ops1,811.52,216.02,353.12,206.3
+ Other Comprehensive Income20.019.7183.8184.6
Total Comprehensive Income1,831.52,235.12,535.02,388.8
Net Income to Common1,795.82,165.52,301.82,157.5
Minority Interest15.749.949.446.7
Per Share
Basic EPS150.19181.11192.51180.44
Diluted EPS150.19181.11192.51180.44
Other Comprehensive Income — detail
+ Other Comprehensive Income19.7183.8184.6
+ Items NOT to be Reclassified to P&L-9.3-21.812.114.3
+ Tax on Items NOT to be Reclassified-3.0-7.23.83.3
+ Tax on Items NOT to be Reclassified — alt tag-3.0
+ Items to be Reclassified to P&L26.434.3175.5173.5
Comprehensive Income — Owners of Parent20.72,186.22,484.21,575.4
Comprehensive Income — Non-controlling Interests-0.648.950.834.3
Per Share — as-filed variants
Basic EPS — Continuing Operations150.19181.11192.51180.44
Diluted EPS — Continuing Operations150.19181.11192.51180.44
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit7,730.08,200.39,619.59,958.4
Gross Margin %61.0263.2565.3866.03
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)2,144.62,527.03,045.73,059.6
− Exceptional Items (reconciliation)-121.50.0-174.8-187.8
Net Income Adj (tax-effected)1,920.22,215.42,494.52,348.5
EPS Adj159.21181.11204.24192.25
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital23.923.923.923.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.